January 22, 2018 / 1:15 PM / a month ago

BRIEF-Teva Announces Top-Line Results From III Studies Of Reslizumab

Jan 22 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA ANNOUNCES TOP-LINE RESULTS FROM PHASE III STUDIES OF SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA

* TEVA - PHASE III REGISTRATION STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB (110 MG) IN A PRE-FILLED SYRINGE DID NOT MEET PRIMARY ENDPOINT

* TEVA - PHASE III CLAIM-SUPPORT STUDY EVALUATING SUBCUTANEOUSLY ADMINISTERED RESLIZUMAB IN PATIENTS WITH OCS-DEPENDENT ASTHMA DID NOT MEET PRIMARY ENDPOINT

* TEVA -NO NEW SAFETY CONCERNS TO KNOWN SAFETY PROFILE, NO CASES OF ANAPHYLAXIS RELATED TO RESLIZUMAB IDENTIFIED IN REVIEW OF DATA FROM STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below